首页PRENW • NASDAQ
add
Prenetics Global Ltd
市场资讯
财务信息
损益表
收入
净收入
(USD) | 2024年9月info | 年同比变化 |
---|---|---|
收入 | 777.80万 | 59.86% |
经营支出 | 1575.58万 | 2.99% |
净收入 | -1067.22万 | 21.36% |
净利润率 | -137.21 | 50.80% |
每股收益 | — | — |
息税折旧摊销前利润 | -1070.63万 | 14.43% |
有效税率 | 0.62% | — |
资产负债表
总资产
负债总额
(USD) | 2024年9月info | 年同比变化 |
---|---|---|
现金及短期投资 | 4868.96万 | -45.29% |
总资产 | 2.36亿 | -14.71% |
负债总额 | 5567.04万 | 16.88% |
权益总额 | 1.80亿 | — |
发行在外的股份 | 1272.28万 | — |
市净率 | 0.00 | — |
资产回报率 | -12.59% | — |
资本回报率 | -15.54% | — |
现金流
现金净变动
(USD) | 2024年9月info | 年同比变化 |
---|---|---|
净收入 | -1067.22万 | 21.36% |
来自运营的现金 | — | — |
投资现金 | — | — |
融资现金 | — | — |
现金净变动 | — | — |
自由现金流 | — | — |
简介
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
成立时间
2014
员工数量
322